ロード中...
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
Lung cancer is the leading cause of cancer death in the United States. The vast majority of patients are diagnosed with metastatic disease with a 5-year survival rate of less than 5%. After first-line chemotherapy or biomarker-matched targeted therapy, only suitable for a small group of patients, fu...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066544/ https://ncbi.nlm.nih.gov/pubmed/27800034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016661164 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|